An intuitive, results-oriented, and collaborative innovator with >20 years of experience in the US pharmaceutical industry, Raj has contributed to the clinical pharmacology components of over 40 INDs; to the design, development, execution, and reporting of over 200 Phase 1/1b studies; and to the worldwide registration of 9 new molecular entities, spanning many therapeutic areas.
Raj’s areas of interest includes the application of novel approaches to new drug development by leveraging decisionable biomarkers and quantitative methods to maximize the probability of development success. During his career, he has been credited with numerous scientific and strategic accomplishments, most notable of which as the principal architect of quantitative clinical pharmacology at Merck, a concept that gained widespread industry adoption.
Raj received his Ph.D. in pharmaceutical sciences from the University of British Columbia, Canada and a mid-career MBA from Warwick Business School, UK. He is an elected fellow of the American Association of Pharmaceutical Scientists and American College of Clinical Pharmacology. Raj sits on the editorial board of the Journal of Clinical Pharmacology and BMC Medicine and has published over 80 peer-reviewed publications in leading journals such as The Lancet, Cancer Research, and Clinical Pharmacology and Therapeutics. In addition, he has edited or co-edited 4 books on new drug development as it relates to translational medicine, dose selection, biopharmaceutics and pharmacokinetics. Raj is an adjunct assistant professor of pharmacology and therapeutics at Thomas Jefferson University and takes an active interest in education initiatives.